## Exhibit 1

```
UNITED STATES DISTRICT COURT
1:1
 2
         DISTRICT OF MASSACHUSETTS
 3 In re: PHARMACEUTICAL
 4 INDUSTRY AVERAGE WHOLESALE
 5 PRICE LITIGATION
                            MDL No. 1456
 6 ------ C/A No. 01-12257-PBS
 7 THIS DOCUMENT RELATES TO:
                                   HON. PATTI B. SARIS
 8 UNITED SATES OF AMERICA ex rel.
 9 VEN-A-CARE OF FLORIDA KEYS, Inc.,
10 et al. v. DEY, INC., et al.,
11 CIVIL ACTION NO. 05-11084-PBS
13 DEPOSITION OF: W. DAVID BRADFORD, Ph.D., VOL. I
               May 7, 2009
14 DATE:
15 TIME:
              9:07 AM
16 LOCATION:
                  Offices of the United States
           Attorney for the District
17
           of South Carolina
18
            151 Meeting Street, Suite 200
19
20
           Charleston, SC
                  Counsel for the Plaintiffs
21 TAKEN BY:
22 REPORTED BY:
                   Laura J. Bash, RPR
2: 1 APPEARANCES OF COUNSEL:
      ATTORNEYS FOR THE PLAINTIFF
 2
 3
        UNITED STATES OF AMERICA:
 4
        U.S. DEPARTMENT OF JUSTICE
 5
        UNITED STATES ATTORNEY'S OFFICE
 6
        BY: GEORGE B. HENDERSON, II
           ASSISTANT U.S. ATTORNEY
 7
 8
        John Joseph Moakley
 9
        Federal Courthouse
 10
         1 Courthouse Way, Suite 9200
         Boston, MA 02210
11
12
         (617) 748-3272
         george.henderson@usdoj.gov
13
```

## 70:15 + 74.2

- 70:15 Q. Appendix F, do you remember whether you 16 wrote this?
  - 17 A. This was written at my request,
  - 18 including the figure.
  - 19 Q. Do you know who wrote it?
  - A. I don't. In essence, this section is
  - 21 summarizing -- it's summarizing steps that were
  - 22 taken -- briefly, it's summarizing in words steps
  - 71: 1 that were taken in this Stata code that were used
    - 2 for much of the analysis. It was a relatively
    - 3 mechanical process to describe succinctly what was
    - 4 undertaken in each of those scrips.
    - 5 Each state has a somewhat different
    - 6 data structure and, therefore, required a
    - 7 different -- a slightly different script in order
    - 8 to make sure that we were pulling the right data
    - 9 elements. And I wanted to have in the appendix for
    - 10 each one, at least in case I was asked a question,
    - 11 a brief summary of what happened. And so I asked 12 that it be provided.
    - 13 Q. Yeah. Paragraph 32 on Page 66 has a
    - 14 sentence that says: I have reviewed the research
    - 15 compiled by Myers and Stauffer for use in
    - 16 Dr. Duggan's analysis and generally feel that this
    - 17 information is accurate. Therefore, I used the
    - 18 Myers and Stauffer data in my analyses.
    - 19 Are you referring there to Myers and
    - 20 Stauffer's summaries of state Medicaid
    - 21 methodologies for reimbursement for prescription 22 drugs?
- 72: 1 A. Yes. And that's in two forms. One is
  - 2 a set of files that was provided where they, Myers
  - 3 and Stauffer, went back and didn't just rely on the
  - 4 National Pharmaceutical Council summaries but
  - 5 called state Medicaid agencies and, my
  - 6 understanding, is filled in gaps that were in that.
  - Also Myers and Stauffer has done a
  - 8 series of reports for states over the years that
  - 9 has this information in it as well. And I reviewed

- 10 both sets of documents.
- Q. Did you conclude that, as far as you
- 12 could tell -- well, let me back up.
- 13 Are you familiar with a series of kind
- 14 of spreadsheet summaries, mostly one page each,
- 15 sometimes two pages each, which summarize
- 16 information -- historical information about the
- 17 state -- each state's drug payment methodology?
- 18 A. I am familiar with a spreadsheet -- a
- 19 set of spreadsheets that resemble what you're 20 describing.
- Q. Do you recall they were produced as
- 22 part of Professor Duggan's -- the backup to
- 73: 1 Professor Duggan's expert report?
  - 2 A. That's my recollection.
  - Q. And did you conclude that, to the best
  - 4 that you could see, that those summaries appeared
  - 5 to be accurate?
  - 6 A. Yes.
  - 7 Q. Did you feel they were accurate enough
  - 8 for you to rely on in your analyses?
  - 9 A. Yes. Let me add that we -- let me add
  - 10 that we also went to original Myers and
  - 11 Stauffer -- I don't remember the exact number, but
  - 12 we have them listed in the report if you want to
  - 13 look at them -- but some dozen, two dozen or so,
  - 14 Myers and Stauffer reports across many states
  - 15 across many years; examined that data as well.
  - So -- and we examined individually all
  - 17 of the National Pharmaceutical Council reports for
  - 18 the year spanning the time period in question. So
  - 19 we did our own background look at a variety of 20 sources.
  - Q. Did you find any errors in the Myers
  - 22 and Stauffer summaries?
- 74: 1 A. I can't recall sitting here today that 2 we did -- or didn't, frankly.